On 30 July 2025, Sandoz and Evotec announced that they have signed a non-binding term sheet relating to Sandoz’s potential acquisition of Just-Evotec Biologics EU and its J.POD® biologics manufacturing facility in Toulouse, France. Under the proposed arrangement, Sandoz would also be granted access to Evotec’s proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology licence.
The proposed transaction would result in Sandoz acquiring 100% of the issued and outstanding equity interest of Just-Evotec for approximately USD 300 million. According to Evotec, the deal will further encompass additional technology related consideration, future development revenues, milestones and product royalties.
Sandoz intends to use the Toulouse site to develop and manufacture Sandoz biosimilars, reinforcing its in-house biosimilar capabilities, while creating additional strategic flexibility. Upon completion of the proposed transaction, Just-Evotec’s employees would transfer with the acquired entity and would become part of the Sandoz Group. Finalisation of the proposed transaction is subject to negotiation of contractual details and obtaining necessary approvals.
Sandoz and Just-Evotec have partnered in relation to the development and manufacturing of biosimilars since May 2023. That partnership was expanded in July 2024.
On 1 July 2025, Sandoz announced that it had commenced construction of a new biosimilar production centre in Slovenia, due to open in 2028, to expand Sandoz’s European biosimilar manufacturing capacity.